GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-09-20| Trials & Approvals

Merck’s Phase 2 HIV Treatment Study Resumes with Phase 3 Program Announcement

by Max Heirich
Share To

On September 20, Merck announced the initiation of a Phase 3 clinical program studying once-daily islatravir an HIV-1 treatment. This announcement comes as the Phase 2 trial evaluating islatravir resumes with amended conditions. The new studies will evaluate islatravir in combination with doravirine.

Related Article: A Cure for HIV Could Be Here Sooner Than You Think – Future of Health

How Does Islatravir Work?

Islatravir is an investigational treatment belonging to a group of HIV drugs known as nucleoside reverse transcriptase translocation inhibitors (NRTTIs). NRTIs inhibit an HIV enzyme called reverse transcriptase, which the virus uses to convert its RNA to DNA. When NRTIs prevent this function, HIV cannot replicate.

Another example of an NRTTI is VIDEX (didanosine). Approved by the United States Food and Drug Administration (FDA) in 2000, it treats HIV-1 infections in combination with other drugs, similar to islatravir.

Several Phase 2 Studies were evaluating islatravir in 2021. Notable among them is NCT05052996. The purpose of this study was the evaluation of the efficacy of islatravir in combination with the investigational capsid inhibitor lenacapavir. However, on December 13, 2021, the FDA placed holds on all islatravir clinical trials. The basis of this hold was the observation of decreases in total lymphocyte and CD4+ T-cell counts in some participants of the studies. 

With Merck’s Phase 3 program announcement, the Phase 2 trial resumes, albeit with a lower dose of islatravir.

What will the Phase 3 Program Evaluate?

The plan for Merck’s new Phase 3 studies is the evaluation of a once-daily lower dose of islatravir in combination with doravirine 100 mg (DOR/ISL). One study of the program plans to evaluate DOR/ISL in previously untreated adults with HIV-1 infection. Meanwhile, two other studies will evaluate DOR/ISL as a switch in antiretroviral therapy (ART) in virologically suppressed adults with HIV-1 infection. 

The Phase 2 NCT05052996 trial will resume, similarly with a lower dose of islatravir. However, Merck also announced the discontinuation of the ongoing Phase 3 PrEP once-monthly oral islatravir trial. Merck will continue to monitor participants from the study.

On the new program Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer at Merck Research Laboratories, said, “We are grateful to the study investigators and the many participants in the trials of islatravir. Following extensive evaluations and consultation with FDA, we are pleased to be able to initiate our new Phase 3 clinical program to evaluate islatravir for the treatment of HIV-1 infection.”

With the FDA reviewing and agreeing with Merck’s plan, the new clinical trials will begin in the near future. As for NCT05052996, Merck expects its primary completion in August 2023, with its total completion following in December 2027.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Pharma’s Growing (R)evolution: Sustainability and Innovations Shaping the Industry
2025-01-07
Biotech Giants Behind Partnerships in Precision Therapies, Gene Editing, and ADCs
2025-01-03
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top